ChartRow logo
PeersILMNMEDPAGHMTDIQV
Share this page

NTRA — Natera Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in NTRA be worth today? →
NTRA returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$391.03
YTD price return
+70.69%
YTD total return
+70.69%
Next earnings
Nov 5, 2026 · After close
Market cap
56.4B
Enterprise value
55.5B
Shares outstanding
144.1M
52W low
$181.00
52W high
$437.41
From 52W high
-10.60%
From 52W low
+116.04%
52W range
82%$181–$437
Beta
1.50

Volume

Rel volume
1.54×
30D volume
1.8M
30D $ vol
724.9M

Insider trading

Insider net 1W
−$4.7M
Insider net 1M
−$33.7M
Insider net 3M
−$110.9M
Insider net 1Y
−$324.5M

Form 4 transactions by trade date, as filed; latest on file 2026-11-03.

Fundamentals

Sales (ttm)
2.7B
Sales/share
$18.78
EPS (ttm)
-$1.37
FCF (ttm)
84.2M
FCF/share
$0.58
Book value/share
$12.64
Net margin
-7.11%
ROE
-10.56%
ROA
-7.24%
Current ratio
3.00

Growth (CAGR, ttm) · 10Y

Sales
+37.85%+42.72%+39.92%+29.03%
FCF
-19.48%n/an/an/a
Shares
+5.03%+7.94%+8.98%+10.78%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+31.25%+32.21%+28.39%+16.47%
FCF/share
-23.34%n/an/an/a
Book value/share
+39.21%+34.42%+31.70%+14.86%
Price
+99.14%+108.97%+28.72%+47.30%
Total return
+99.14%+108.97%+28.72%+47.30%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-284.8×
Fwd P/E
-2130.7×
P/S (ttm)
20.8×
P/B (mrq)
30.9×
P/FCF (ttm)
669.4×
EV/Sales (ttm)
20.5×
FCF yield (ttm)
0.15%
Buyback yield (realized, 1y)
-5.03%
Shareholder yield (realized, 1y)
-5.03%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
93rd
P/B
90th

Bar = where today’s multiple sits in NTRA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+0.62%
5D
-7.87%
1M
-4.71%
3M
+42.09%
YTD
+70.69%
1Y
+99.05%
5Y
+253.33%
1D
+0.62%
5D
-7.87%
1M
-4.71%
3M
+42.09%
YTD
+70.69%
1Y
+99.05%
5Y
+253.33%

Fundamentals#

Revenue

5Y CAGR +42.6%10Y CAGR +28.3%YoY +37.7%
$2.7B TTM$752.8M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$289.7M TTM−$75.8M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

EPS (diluted)

5Y n/m10Y n/mYoY n/m
−$1.37 TTM−$0.47 Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
$84.2M TTM−$8.6M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $228.2M, capex −$144M

Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Q2 2026: operating cash flow $54.8M, capex −$63.4M

Shares (diluted)

5Y +68.8%10Y +421.8%YoY +5.1%
140.1M TTM143.3M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Net income

5Y n/m10Y n/mYoY n/m
−$192.3M TTM−$67M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Full NTRA financials →

About Natera#

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.

Austin, TX·4,424 employees·Diagnostics & Research·natera.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding NTRA#

24 of the 193 ETFs ChartRow carries live hold NTRA. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF2.9%
ARKKARK Innovation ETF1.2%
XBISPDR S&P Biotech ETF1.2%
VBKVanguard Small-Cap Growth ETF1.0%
IWPiShares Russell Mid-Cap Growth ETF1.0%
VHTVanguard Health Care ETF0.6%
VXFVanguard Extended Market ETF0.5%
VBVanguard Small-Cap ETF0.4%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%